Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Biopharma Struggling with Enshi Acquisition

publication date: Aug 15, 2007
Revenues Grow in Q2 -- China Biopharmaceuticals (CHBP.OB) reported higher revenue and gross profit in its second quarter. Revenues moved up to $8.9 million, a 28% increase over the year earlier, and gross profits were 18% higher at $2.2 million, though the company reported a net loss of $30,000, in part because of financing activities.The company reports it is continuing to have difficulty with its year-old purchase of Shenyang Enshi Pharmaceutical Limited Company (Enshi). More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital